Efficacy of Riluzole for Cervical Spondylotic Myelopathy with Surgery
CSM (cervical spondylotic myelopathy) is the most common cause of spinal cord injury worldwide. While there is recent evidence that surgical decompression is an effective treatment for CSM, not all patients have complete resolution of their neurological symptoms. Given this background and data from preclinical models of non-traumatic and traumatic spinal cord injury, there is strong evidence to consider the potential benefit of adding a neuroprotective drug that aids in the treatment of patients with CSM who are undergoing surgical decompression. Riluzole is FDA-approved for the treatment of amyotrophic lateral sclerosis, which has some similar clinical features to CSM. Riluzole is currently under investigation for traumatic spinal cord injury. Given this background, there is a strong basis to consider studying the potential neurological benefits of Riluzole as a treatment for surgical decompression in patients with CSM.
In order to participate you must meet the following criteria:
- Are between 18 and 80 years of age.
- Have a diagnosis of symptomatic cervical spondylotic myelopathy.
- Have MRI evidence of cervical spondylotic myelopathy.
- Are scheduled for an elective surgery for cervical spondylotic myelopathy.
You will be excluded from the study if any of the following criteria apply to you:
- Have had a previous surgery for CSM.
- Have concomitant symptomatic lumbar stenosis.
- Have CSM symptoms due to cervical trauma (at the discretion of the investigator).
- Have an abnormal absolute neutrophil count, creatinine, or liver enzymes (ALT or AST) at screening visit.
This is a partial list of eligibility requirements.